You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 4
  • O009/#786 Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious brca mutation: efficacy and safety from ariel4, a randomized phase 3 study

Citation Tools

Article menu

Download PDFPDF

Oral Abstracts
Awards Ceremony & Plenary 4: Seminal Abstract Presentations
O009/#786 Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious brca mutation: efficacy and safety from ariel4, a randomized phase 3 study
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Kristeleit R, Lisyanskaya A, Fedenko A, et al
O009/#786 Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious brca mutation: efficacy and safety from ariel4, a randomized phase 3 study
International Journal of Gynecologic Cancer 2021;31:A5-A6.